Research from Sweden indicates that weight-loss surgery and metabolic treatments could have long-term benefits for brain health, highlighting the importance of addressing obesity and diabetes in dementia prevention. Swedish researchers have found an association between bariatric surgery and a lower…
A Swedish research study suggests that weight-loss surgery could significantly lower the risk of dementia among people with obesity and type 2 diabetes, highlighting potential broader neurological benefits. A Swedish study from Örebro University and Karolinska Institutet suggests that bariatric…
Wayne State University has secured a $5.7 million NIH grant to investigate why some lean individuals develop insulin resistance while some obese individuals remain sensitive, aiming to uncover new biological insights and therapeutic targets for type 2 diabetes. Wayne State…
Preliminary research presented at the European Association for the Study of Diabetes highlights a potential biological mechanism linking red meat consumption to increased risk of type 2 diabetes, focusing on the role of the sugar Neu5Gc and its immune response.…
A comprehensive international study involving nearly 100,000 patients finds no significant link between semaglutide and pancreatic cancer, offering reassurance amid ongoing safety debates. Semaglutide does not appear to raise the risk of pancreatic cancer, according to research presented at the…
A groundbreaking study demonstrates that children with newly diagnosed type 1 diabetes exhibit diverse biological signatures based on age at onset, suggesting the need for age-specific diagnostic and treatment approaches. Type 1 diabetes is increasingly being viewed as more than…
An experimental drug, retatrutide, has demonstrated significant weight loss and improved blood sugar control in mid-stage clinical trials, positioning it as a potential breakthrough in treating both obesity and type 2 diabetes. Experts caution against unregulated online sales as the…
An experimental Eli Lilly drug, retatrutide, has demonstrated substantial weight loss and improved blood-sugar control in people with type 2 diabetes, signalling a potential breakthrough in metabolic health treatments. An experimental Eli Lilly obesity drug has helped people with type…
Eli Lilly’s experimental drug retatrutide delivers significant weight loss and blood sugar improvements in phase 3 trials, potentially transforming treatment for obesity and type 2 diabetes, with regulatory approval sought in 2027. Retatrutide, an experimental obesity and diabetes drug being…
Emerging research suggests that shifts in gut bacteria could precede traditional blood glucose markers, offering potential early warning signs for type 2 diabetes risk. Researchers are increasingly looking beyond blood sugar alone for early signs of type 2 diabetes risk.…
